Wednesday, July 8, 2026

pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX

Travere Therapeutics

Travere Therapeutics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US HQ
2020 Founded
506 Employees
Public company Type
TVTX · NYSE Ticker
Company details
Status
Public
HQ
3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
Founded
2020
Employees
506
Programs
13
Drugs
9
Patents
1
Intelligence · Clinical Programs

Travere Therapeutics projects

1 ClinicalTrials.gov programs sponsored by Travere Therapeutics.

Travere Therapeutics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Sparsentan

    Travere Therapeutics

    Proteinuria

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Travere Therapeutics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.